Hutchin Hill Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Hutchin Hill Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$242K	Sell	1,800 -6,575	-79%	-$912K	0.07%	306
2017 Q3	$1.23M	Hold	8,375	–	–	0.05%	298
2017 Q2	$1.3M	Sell	8,375 -11,525	-58%	-$1.76M	0.04%	435
2017 Q1	$2.89M	Buy	+19,900	New	+$2.59M	0.08%	259
2016 Q4	–	Sell	-2,800	Closed	-$340K	–	770
2016 Q3	$340K	Sell	2,800 -6,700	-71%	-$903K	0.01%	501
2016 Q2	$1.34M	Buy	+9,500	New	+$1.4M	0.05%	240
2016 Q1	–	Sell	-44,875	Closed	-$6.31M	–	704
2015 Q4	$6.31M	Buy	44,875 +28,345	+171%	+$3.93M	0.16%	112
2015 Q3	$2.19M	Sell	16,530 -4,270	-21%	-$735K	0.08%	283
2015 Q2	$3.66M	Buy	+20,800	New	+$3.74M	0.09%	200
2015 Q1	–	Sell	-6,500	Closed	-$1.06M	–	736
2014 Q4	$1.06M	Sell	6,500 -3,700	-36%	-$614K	0.04%	316
2014 Q3	$1.64M	Buy	10,200 +4,500	+79%	+$692K	0.06%	275
2014 Q2	$838K	Buy	+5,700	New	+$791K	0.04%	381
2014 Q1	–	Sell	-21,200	Closed	-$2.68M	–	659
2013 Q4	$2.68M	Buy	+21,200	New	+$2.19M	0.18%	85
2013 Q3	–	Sell	-14,800	Closed	-$1.02M	–	527
2013 Q2	$1.02M	Buy	+14,800	New	+$905K	0.1%	117

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Hutchin Hill Capital's JAZZ Position: Q4 2017 in Review

Hutchin Hill Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 79% in Q4 2017, selling an estimated $912K and leaving 1,800 shares worth $242K. The position accounts for 0.07% of the portfolio, ranked #306.

Hutchin Hill Capital first reported a position in JAZZ in Q2 2013 and has held it in 14 quarters since. The position peaked at $6.31M in Q4 2015. 323 funds tracked by Wall St. Rank hold JAZZ as of Q4 2017.

Hutchin Hill Capital held 1,800 shares of Jazz Pharmaceuticals worth $242K as of Q4 2017.
Hutchin Hill Capital sold 6,575 Jazz Pharmaceuticals shares in Q4 2017, an estimated $912K.
Jazz Pharmaceuticals made up 0.07% of Hutchin Hill Capital's portfolio in Q4 2017, its #306 holding.
Hutchin Hill Capital first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
Hutchin Hill Capital's Jazz Pharmaceuticals position peaked at $6.31M in Q4 2015.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2017.

Based on Hutchin Hill Capital's 13F filing for Q4 2017, filed 12 Feb 2018.